111 related articles for article (PubMed ID: 21134002)
1. Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: a prospective translational study on a uniformly treated cohort of adult patients.
Srividya MR; Thota B; Shailaja BC; Arivazhagan A; Thennarasu K; Chandramouli BA; Hegde AS; Santosh V
Neuropathology; 2011 Aug; 31(4):376-83. PubMed ID: 21134002
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood.
Korshunov A; Sycheva R; Gorelyshev S; Golanov A
Mod Pathol; 2005 Sep; 18(9):1258-63. PubMed ID: 15832192
[TBL] [Abstract][Full Text] [Related]
3. Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.
Koshiyama DB; Trevisan P; Graziadio C; Rosa RFM; Cunegatto B; Scholl J; Provenzi VO; de Sá AP; Soares FP; Velho MC; de A P Filho N; Oliveira CA; Zen PRG
J Neurooncol; 2017 Dec; 135(3):465-472. PubMed ID: 28856550
[TBL] [Abstract][Full Text] [Related]
4. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.
Boström J; Cobbers JM; Wolter M; Tabatabai G; Weber RG; Lichter P; Collins VP; Reifenberger G
Cancer Res; 1998 Jan; 58(1):29-33. PubMed ID: 9426052
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity and uniparental disomy of chromosome region 10q23.3-26.3 in glioblastoma.
Alekseeva EA; Kuznetsova EB; Tanas AS; Prozorenko EV; Zaytsev AM; Kurzhupov MI; Kirsanova ON; Rudenko VV; Strelnikov VV; Zaletaev DV
Genes Chromosomes Cancer; 2018 Jan; 57(1):42-47. PubMed ID: 28960585
[TBL] [Abstract][Full Text] [Related]
6. The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years.
Korshunov A; Sycheva R; Golanov A
Cancer; 2005 Aug; 104(4):825-32. PubMed ID: 15981281
[TBL] [Abstract][Full Text] [Related]
7. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
Yoshimoto M; Cunha IW; Coudry RA; Fonseca FP; Torres CH; Soares FA; Squire JA
Br J Cancer; 2007 Sep; 97(5):678-85. PubMed ID: 17700571
[TBL] [Abstract][Full Text] [Related]
8. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications.
Yoshimoto M; Ludkovski O; DeGrace D; Williams JL; Evans A; Sircar K; Bismar TA; Nuin P; Squire JA
Genes Chromosomes Cancer; 2012 Feb; 51(2):149-60. PubMed ID: 22045666
[TBL] [Abstract][Full Text] [Related]
9. Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas.
Sanson M; Leuraud P; Aguirre-Cruz L; He J; Marie Y; Cartalat-Carel S; Mokhtari K; Duffau H; Delattre JY; Hoang-Xuan K
J Neurosurg; 2002 Dec; 97(6):1397-401. PubMed ID: 12507139
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.
Fujisawa H; Kurrer M; Reis RM; Yonekawa Y; Kleihues P; Ohgaki H
Am J Pathol; 1999 Aug; 155(2):387-94. PubMed ID: 10433932
[TBL] [Abstract][Full Text] [Related]
11. PTEN signaling pathways in glioblastoma.
Koul D
Cancer Biol Ther; 2008 Sep; 7(9):1321-5. PubMed ID: 18836294
[TBL] [Abstract][Full Text] [Related]
12. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.
Mott RT; Turner KC; Bigner DD; McLendon RE
J Neurosurg; 2008 Feb; 108(2):330-5. PubMed ID: 18240930
[TBL] [Abstract][Full Text] [Related]
13. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
Teng DH; Hu R; Lin H; Davis T; Iliev D; Frye C; Swedlund B; Hansen KL; Vinson VL; Gumpper KL; Ellis L; El-Naggar A; Frazier M; Jasser S; Langford LA; Lee J; Mills GB; Pershouse MA; Pollack RE; Tornos C; Troncoso P; Yung WK; Fujii G; Berson A; Steck PA
Cancer Res; 1997 Dec; 57(23):5221-5. PubMed ID: 9393738
[TBL] [Abstract][Full Text] [Related]
14. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.
Wang SI; Parsons R; Ittmann M
Clin Cancer Res; 1998 Mar; 4(3):811-5. PubMed ID: 9533551
[TBL] [Abstract][Full Text] [Related]
15. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
[TBL] [Abstract][Full Text] [Related]
16. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
17. Functional evaluation of p53 and PTEN gene mutations in gliomas.
Kato H; Kato S; Kumabe T; Sonoda Y; Yoshimoto T; Kato S; Han SY; Suzuki T; Shibata H; Kanamaru R; Ishioka C
Clin Cancer Res; 2000 Oct; 6(10):3937-43. PubMed ID: 11051241
[TBL] [Abstract][Full Text] [Related]
18. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.
Pollack IF; Hamilton RL; James CD; Finkelstein SD; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL;
J Neurosurg; 2006 Nov; 105(5 Suppl):418-24. PubMed ID: 17328268
[TBL] [Abstract][Full Text] [Related]
19. Variable phenotypes associated with 10q23 microdeletions involving the PTEN and BMPR1A genes.
Menko FH; Kneepkens CM; de Leeuw N; Peeters EA; Van Maldergem L; Kamsteeg EJ; Davidson R; Rozendaal L; Lasham CA; Peeters-Scholte CM; Jansweijer MC; Hilhorst-Hofstee Y; Gille JJ; Heins YM; Nieuwint AW; Sistermans EA
Clin Genet; 2008 Aug; 74(2):145-54. PubMed ID: 18510548
[TBL] [Abstract][Full Text] [Related]
20. PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma.
Kato H; Fujimura M; Kumabe T; Ishioka C; Kanamaru R; Yoshimoto T
J Clin Neurosci; 2004 Jan; 11(1):37-41. PubMed ID: 14642363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
